Intellipharmaceutics Logo

Email this page: News Release

Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Intellipharmaceutics for any marketing purposes.

Send:       


 
This helps Intellipharmaceutics prevent automated submissions.